Search This Blog

Thursday, June 1, 2023

Amarin Partner Approval for Vascepa® (Icosapent Ethyl) in Mainland China

 - VASCEPA Approved by the National Medical Products Administration (NMPA) as an Adjunct to Diet to Reduce Triglyceride Levels in Adult Patients with Severe Hypertriglyceridemia (≥ 500 mg/dL) --

-- EddingPharm Now Working Towards Preparing for Commercial Launch of VASCEPA Across Mainland China Expected by Year-End --

https://finance.yahoo.com/news/amarin-partner-eddingpharm-receives-regulatory-100000116.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.